TP53 and neoplasm: This reflects the unavoidable on-target, off-tumor activation of wild-type p53 in normal tissues with high proliferative turnover, particularly hematopoietic stem cells and gastrointestinal epithelium, which results in an irreducibly narrow therapeutic window (Wang W. et al., 2024).